


PRODUCT INFORMATION



Lazabemide

Item No. 11640

CAS Registry No.: 103878-84-8
Formal Name: N-(2-aminoethyl)-5-chloro-2-pyridinecarboxamide
Synonym: Ro 19-6327/000
MF: C₈H₁₀ClN₃O
FW: 199.6
Purity: ≥95%
UV/Vis.: λ_{max}: 230, 274 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Lazabemide is supplied as a crystalline solid. A stock solution may be made by dissolving the lazabemide in the solvent of choice, which should be purged with an inert gas. Lazabemide is soluble in the organic solvent methanol at a concentration of approximately 2 mg/ml.

Lazabemide is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, lazabemide should first be dissolved in methanol and then diluted with the aqueous buffer of choice. Lazabemide has a solubility of approximately 0.1 mg/ml in a 1:10 solution of methanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Lazabemide is an inhibitor of monoamine oxidase B (MAO-B; K_i = 0.084 μM).¹ It is selective for MAO-B over MAO-A (IC₅₀s = 0.02 and 640 μM, respectively).² Lazabemide inhibits rat liver MAO-B *ex vivo* with an ED₅₀ value of 53 nmol/kg.³ It inhibits ischemia-reperfusion injury-induced hydroxyl radical formation in mouse cerebral ventricles when administered at a dose of 3 mg/kg.⁴

References

1. Cesura, A.M., Gottowik, J., Lahm, H.W., *et al.* Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesis. *Eur. J. Biochem.* **236**(3), 996-1002 (1996).
2. Ozaita, A., Olmos, G., Boronat, M.A., *et al.* Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I₂-imidazoline receptors in rat liver. *Br. J. Pharmacol.* **121**(5), 901-912 (1997).
3. Henriot, S., Kuhn, C., Kettler, C., *et al.* Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findings. *J. Neural Transm. Suppl.* **41**, 321-325 (1994).
4. Suzuki, T., Akaike, N., Ueno, K., *et al.* MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice. *Pharmacology* **50**(6), 357-362 (1995).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM